Vaccine immunotherapy in lung cancer: Clinical experience and future directions

Pharmacology and Therapeutics

Volumn 153, Issue , 2015, Pages 1-9

  Freeman Keller, Morganna ^a   Goldman, Jamie ^a   Gray, Jhanelle ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Abscopal effect; Immunotherapy; Non small cell lung cancer; Small cell lung cancer; Vaccine therapy

Indexed keywords

BCG VACCINE; BELAGENPUMATUCEL L; CANCER VACCINE; CIMAVAX EPIDERMAL GROWTH FACTOR VACCINE; GMCD 40L; INGN 225; MELANOMA ANTIGEN ENCODING GENE A3 VACCINE; MITUMOMAB; NY ESO 1 ANTIGEN; TECEMOTIDE; TG 4010; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER MODEL; CANCER PATIENT; CANCER PROGNOSIS; HUMAN; IMMUNOSURVEILLANCE; MOLECULAR BIOLOGY; NON SMALL CELL LUNG CANCER; PERSONAL EXPERIENCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMALL CELL LUNG CANCER; SURVIVAL RATE; TREATMENT RESPONSE; ANIMAL; CARCINOMA, NON-SMALL-CELL LUNG; IMMUNOLOGY; IMMUNOTHERAPY; LUNG NEOPLASMS; MULTIMODALITY CANCER THERAPY; PROCEDURES; SMALL CELL LUNG CARCINOMA; TRENDS; VACCINATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; SMALL CELL LUNG CARCINOMA; VACCINATION;

EID: 84938416174     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2015.05.004     Document Type: Review

References (59)

1. B. Agrawal, K. M., M.A. Reddish, and B.M. Longenecker Rapid induction of primary human CD4+ and CD8+ T cell responses against cancer-associated MUC1 peptide epitopes International Immunology 10 1998 1907 1916
2. S.J. Antonia, M. N., I. Fricke, A. Chiappori, P. Thompson, N. Williams, and et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer Clinical Cancer Research 12 2006 878 887
3. L. Bazhenova, G. G., J.J. Nemunaitis, E. Juhász, R. Ramlau, M.M. van den Heuvel, and et al. An international, multicenter, randomized, double-blind phase III study of maintenance belagenpumatucel-l in non-small cell lung cancer (NSCLC): updated analysis of patients enrolled within 12 weeks of completion of chemotherapy Journal of Clinical Oncology 32 2014 5 2014 (suppl; abstr 8056)
4. J.R. Brahmer, S.S. Tykodi, L.Q. Chow, W.J. Hwu, S.L. Topalian, P. Hwu, and et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer The New England Journal of Medicine 366 2012 2455 2465
5. C. Butts, A. Maksymiuk, G. Goss, D. Soulieres, E. Marshall, Y. Cormier, and et al. Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial Journal of Cancer Research and Clinical Oncology 137 2011 1337 1342
6. C.A. Butts, P. Mitchell, L. Havel, J.M. Krzakowski, S. Nawrocki, and T.E. Ciuleanu START: a phase III study of L-BLP25 cancer immunotherapy for unresectable stage III nonsmall cell lung cancer Journal of Clinical Oncology 31 2013 7500
7. C. Butts, N. Murray, A. Maksymiuk, G. Goss, E. Marshall, D. Soulieres, and et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer Journal of Clinical Oncology 23 2005 6674 6681
8. S. Chada, A. Mhashilkar, J.A. Roth, and D. Gabrilovich Development of vaccines against self-antigens: the p53 paradigm Current Opinion in Drug Discovery & Development 6 2003 169 173
9. J.E. Chaft, A. Litvak, M.E. Arcila, P. Patel, S.P. D'Angelo, L.M. Krug, and et al. Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation Clinical Lung Cancer 15 2014 405 410
10. Q. Chen, H. Jackson, M. Shackleton, P. Parente, W. Hopkins, S. Sturrock, and et al. Characterization of antigen-specific CD8ρ T lymphocyte responses in skin and peripheral blood following intradermal peptide vaccination Cancer Immunity 5 2005 5
11. A. Chiappori, S. Antonia, C. Williams, M. Pinder-Schenck, T. Tanvetyanon, J. Gray, and et al. P53 dendritic cell vaccine in small cell lung cancer Journal of Thoracic Oncology 9 9 2014 Supp 3
12. S. Cohen, and H.L. Kaufman TG-4010 transgene Current Opinion in Investigational Drugs 5 2004 1319 1328
13. B.C. Creelan, S. Antonia, D. Noyes, T.B. Hunter, G.R. Simon, G. Bepler, and et al. Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma Journal of immunotherapy 36 2013 442 450
14. D. D'Amico, D. Carbone, T. Mitsudomi, M. Nau, J. Fedorko, E. Russell, and et al. High frequency of somatically acquired p53 mutations in small cell lung cancer cell lines and tumors Oncogene 7 1992 339 346
15. A.I. Daud, O. Hamid, A. Ribas, F.S. Hodi, W.J. Hwu, R. Kefford, and et al. Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma: correlation of tumor PD-L1 expression with outcome 2014 Annual Meeting: CT104 2014 American Association for Cancer Research
16. S. Dessureault, M. Alsarraj, S. McCarthy, T. Hunter, D. Noyes, D. Lee, and et al. A GM-CSF/CD40L producing cell augments anti-tumor T cell responses The Journal of Surgical Research 125 2005 173 181
17. S. Dessureault, D. Noyes, D. Lee, M. Dunn, W. Janssen, A. Cantor, and et al. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease Annals of Surgical Oncology 14 2007 869 884
18. A. Doyle, W.J. Martin, K. Funa, A. Gazdar, D. Carney, S.E. Martin, and et al. Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer The Journal of Experimental Medicine 161 5 1985 1135 1151
19. H. Fang, R. Yamaguchi, X. Liu, Y. Daigo, S. Miyano, and Y. Nakamura Quantitative T cell receptor (TCR) repertoire analysis by next-generation sequencing (NGS) in non-small cell lung cancer patients treated with therapeutic cancer peptide vaccines Cancer Research 74 2014 3568
20. S.C. Formenti, and S. Demaria Combining radiotherapy and cancer immunotherapy: a paradigm shift Journal of the National Cancer Institute 105 2013 256 265
21. R. Fuentes, R. Allman, and M.D. Mason Ganglioside expression in lung cancer cell lines Lung Cancer 18 1997 21 33
22. G. Giaccone, C. Debruyne, E. Felip, P.B. Chapman, S.C. Grant, M. Millward, and et al. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study) Journal of Clinical Oncology 23 2005 6854 6864
23. S. Gnjatic, H. Nishikawa, A.A. Jungbluth, A.O. Güre, G. Ritter, E. Jäger, and et al. NY-ESO-1: review of an immunogenic tumor antigen 95 2006 1 30
24. E.B. Golden, S. Demaria, P.B. Schiff, A. Chachoua, and S.C. Formenti An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer Cancer Immunology Research 1 2013 365 372
25. G. Gonzalez, T. Crombet, F. Torres, M. Catala, L. Alfonso, M. Osorio, and et al. Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy Annals of Oncology 14 2003 461 466
26. R. Govindan, N. Page, D. Morgensztern, W. Read, R. Tierney, A. Vlahiotis, and et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database Journal of Clinical Oncology 24 2006 4539 4544
27. S.C. Grant, M.G. Kris, A.N. Houghton, and P.B. Chapman Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guerin Clinical Cancer Research 5 1999 1319 1323
28. J. Harper, and R.C. Sainson Regulation of the anti-tumor immune response by cancer-associated fibroblasts Seminars in Cancer Biology 25 2014 69 77
29. S.M. Hiniker, D.S. Chen, S. Reddy, D.T. Chang, J.C. Jones, J.A Mollick, and et al. A systemic complete response of metastatic melanoma to local radiation and immunotherapy Translational Oncology 4 2012 404 407
30. T. Ishida, S. Chada, M. Stipanov, S. Nadaf, F.I. Ciernik, D.I. Gabrilovich, and et al. Dendritic cells transduced with wild-type p53 gene elicit potent anti-tumour immune responses Clinical and Experimental Immunology 117 1999 224 251
31. D.M. Jackman, V.A. Miller, L.A. Cioffredi, B.Y. Yeap, P.A. Janne, G.J. Riely, and et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials Clinical Cancer Research 15 2009 5267 5273
32. K. Kakimi, M. Isobe, A. Uenaka, H. Wada, E. Sato, Y. Doki, and et al. A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen International Journal of Cancer 129 2011 2836 2846
33. A. Macias Combination of Platinum standard first front line chemotherapy and Vaxira vaccine in patients with advanced non-small-cell lung cancer AGE 62 2014 40 75
34. M. Marchand, N. van Baren, P. Weynants, V. Brichard, B. Dreno, M.H. Tessier, and et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1 International Journal of Cancer 80 1999 219 230
35. J.I. Mayordomo, D.J. Loftus, H. Sakamoto, C.M. De Cesare, P.M. Appasamy, M.T Lotze, and et al. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines The Journal of Experimental Medicine 183 1996 1357 1365
36. M. McCaffery, T.J. Yao, L. Williams, P.O. Livingston, A.N. Houghton, and P.B. Chapman Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant Clinical Cancer Research 2 1996 679 686
37. R. Murphy, S. Green, G. Ritter, L. Cohen, D. Ryan, W. Woods, and et al. Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditions Preparative Biochemistry & Biotechnology 35 2005 119.134
38. National Institutes of Health Cancer of all Sites. SEER Stat Fact Sheets vol. 2012 2012
39. National Institutes of Health Cancer of the Lung and Bronchus - SEER Stat Facts Sheet vol. 2012 2012
40. J. Nemunaitis, R.O. Dillman, P.O. Schwarzenberger, N. Senzer, C. Cunningham, J. Cutler, and et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer Journal of Clinical Oncology 24 2006 4721 4730
41. E. Neninger Vinageras, A. de la Torre, M. Osorio Rodriguez, M. Catala Ferrer, I. Bravo, M. Mendoza del Pino, and et al. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer Journal of Clinical Oncology 26 2008 1452 1458
42. M. Palmer, J. Parker, S. Modi, C. Butts, M. Smylie, A. Meikle, and et al. Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer Clinical Lung Cancer 3 2001 49 57 discussion 58
43. C. Pedro, M. Rodríguez, Gryssell Rodríguez, Gisela González, and Agustín Lage Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy MEDICC Review 12 2010
44. M.A. Postow, M.K. Callahan, C.A. Barker, Y. Yamada, J. Yuan, S. Kitano, and et al. Immunologic correlates of the abscopal effect in a patient with melanoma The New England Journal of Medicine 366 2012 925 931
45. E. Quoix, R. Ramlau, V. Westeel, Z. Papai, A. Madroszyk, A. Riviere, and et al. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial The Lancet Oncology 12 2011 1125 1133
46. R. Ramlau, E. Quoix, J. Rolski, M. Pless, H. Lena, E. Levy, and et al. A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV non-small cell lung cancer Journal of Thoracic Oncology 3 2008 735 744
47. T.C. Ramos, E.N. Vinageras, M.C. Ferrer, B.G. Verdecia, I.L. Rupale, L.M. Perez, and et al. Treatment of NSCLC patients with an EGF-based cancer vaccine: report of a Phase I trial Cancer Biology & Therapy 5 2006 145 149
48. M.A. Reddish, G.D. MacLean, S. Poppema, A. Berg, and B.M. Longenecker Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy Cancer Immunology, Immunotherapy 42 1996 303 309
49. C. Rochlitz, R. Figlin, P. Squiban, M. Salzberg, M. Pless, R. Herrmann, and et al. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer The Journal of Gene Medicine 5 2003 690 699
50. P.C. Rodriguez, E. Neninger, B. Garcia, X. Popa, C. Viada, P. Luaces, and et al. Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an Epidermal Growth Factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients Journal Immune Based Therapy Vaccines 9 2011 7
51. S. Sharma, S.C. Yang, S. Hillinger, L.X. Zhu, M. Huang, R.K. Batra, and et al. CCL21-mediated anti-tumor responses require IFNgamma, MIG/CXCL9 and IP-10/CXCL10 Molecular Immunotherapy Cancer 2 2003
52. F.A. Shepherd, J. Rodrigues Pereira, T. Ciuleanu, E.H. Tan, V. Hirsh, S. Thongprasert, and et al. Erlotinib in previously treated non-small-cell lung cancer The New England Journal of Medicine 353 2005 123 132
53. W. Sienel, C. Varwerk, A. Linder, D. Kaiser, M. Teschner, M. Delire, and et al. Melanoma associated antigen (MAGE)-A3 expression in Stages I and II non-small cell lung cancer: results of a multicenter study European Journal of Cardio-Thoracic Surgery 25 2004 11131 11134
54. A. Takano, Y. Nakamura, and Y. Daigo Characterization of LASEP3 as a serological and prognostic biomarker and a therapeutic target for lung cancer Cancer Research 74 2014 868
55. S.H. van der Burg, K. de Cock, A.G. Menon, K.L. Franken, M. Palmen, A. Redeker, and et al. Long lasting p53-specific T cell memory responses in the absence of anti-p53 antibodies in patients with resected primary colorectal cancer European Journal of Immunology 31 2001 146 155
56. J.F. Vansteenkiste, B. Cho, T. Vanakesa, T. De Pas, M. Zielinski, and M.S. Kim MAGRIT, a double blind, randomized, placebo-controlled phase III study to assess the efficacy of the RECMAGE-A3+ AS15 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small cell lung cancer (NSCLC) Annals of Oncology 25 Suppl. 4 2014
57. J. Vansteenkiste, M. Zielinski, A. Linder, J. Dahabreh, E.E. Gonzalez, W. Malinowski, and et al. Adjuvant MAGE-A3 immunotherapy in resected non-small cell lung cancer: phase II randomized study results Journal of Clinical Oncology 31 2013 2396 2403
58. J. Vansteenkiste, M. Zielinski, A. Linder, J. Dahabre, E. Esteban, W. Malinowski, and et al. Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC) ASCO Meeting Abstracts 25 2007 7554
59. Y.L. Wu, K. Park, R.A. Soo, Y. Sun, K. Tyroller, D. Wages, and et al. INSPIRE: a phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer BMC Cancer 11 2011 430